Xeris Biopharma Holdings stock rises 6.65 percent on Nasdaq
Published on 09/28/2026 at 17:57 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Xeris Biopharma Holdings (ISIN US98422E1038) stock was trading at USD 9.71 on Nasdaq at 11:54 a.m. ET on September 28, 2026, up 6.65 percent from the USD 9.10 prior close. The move leaves the shares 3.67 percent below their 52-week high of USD 10.08.
Revenue expands in Q2
In the second quarter ended June 30, 2026, total revenue reached USD 92.1 million, up 29 percent from USD 71.5 million a year earlier, according to Xeris Biopharma in its release dated August 6, 2026. Net product revenue increased 34 percent to USD 91.0 million, led by Recorlev revenue of USD 56.8 million, up 81 percent year over year.
The commercial improvement came with a mixed earnings picture. GAAP net loss widened to USD 31.1 million from USD 1.9 million in the prior-year quarter, primarily because of a one-time non-cash charge of USD 31.0 million linked to convertible-note exchange agreements, the company said in the same August 6 release.
Analysts see room above USD 12
MarketBeat reported on September 21, 2026, that the seven-analyst consensus remained Hold with an average 12-month price target of USD 12.80. The target is 31.82 percent above the USD 9.71 intraday price, while recent published targets ranged from USD 12.00 to USD 16.00.
That valuation gap reflects expectations for continued commercial execution rather than a completed pipeline launch. Xeris tightened full-year 2026 revenue guidance to USD 385 million to USD 390 million in the August 6 release, giving investors a quantified benchmark for the second half.
XP-8121 adds a long-term catalyst
On September 9, 2026, Xeris Biopharma outlined a Phase 3 plan for XP-8121, a once-weekly subcutaneous levothyroxine candidate. The planned Cornerstone study is designed for 500 participants across more than 50 US sites, with topline results expected in late 2028 and a potential launch in 2030.
The company expects XP-8121 to generate peak net revenue of USD 1 billion to USD 3 billion if approved. That opportunity is balanced by clinical, regulatory and commercialization risks, while current results still depend mainly on Recorlev, Gvoke and Keveyis.
Nasdaq price reaches USD 9.71
Xeris Biopharma Holdings stock was last at USD 9.71 on Nasdaq at 11:54 a.m. ET on September 28, 2026. Market capitalization was USD 1.7 billion, and trading volume stood at 1,064,308 shares.
Xeris Biopharma Holdings stock snapshot
- Company: Xeris Biopharma Holdings, Inc.
- ISIN: US98422E1038
- Ticker: XERS
- Trading venue: Nasdaq Global Select Market
- Price (as of September 28, 2026, 11:54 a.m. ET): USD 9.71
- Market capitalization: USD 1.7 billion (as of September 28, 2026)
- 52-week range: USD 5.25-10.08 (as of September 28, 2026)
- Sector / Industry: Health Care / Pharmaceuticals
